Dewi Vernerey: The Results of the ASTER 70s Trial
Dewi Vernerey, Head of the methodology and quality of life unit in oncology at CHU de Besançon, shared on LinkedIn:
“I am delighted to announce that the results of the ASTER 70s trial have just been published in the prestigious journal, The Lancet!
ASTER 70s is the first phase 3 superiority trial investigating the benefit of chemotherapy versus no chemotherapy in the adjuvant setting specifically in women aged 70 years or older with oestrogen receptor-positive breast cancer and at high risk according to genomic grade index (GGI)
The addition of adjuvant chemotherapy to hormonotherapy conferred no statistically significant survival benefit and was associated with more adverse events and worse Health-related Quality of Life.
The ASTER 70s trial provides important information to improve shared decision making between doctor and patient when discussing adjuvant breast cancer treatment.
Despite a large clinical and geriatric assessment deployed in the trial, no subgroup has been identified to more precisely define patients who really benefit from chemotherapy addition to hormonotherapy.
A huge translational research program on tumor and blood samples is now ongoing: ASTER-T (PRTK-23) and ASTER predict (FONDATION ARC-24)
My sincere thanks to Prof. Etienne Brain from Institut Curie for the constant trust in the UMQVC and for the consideration of the role, work and essential commitment of the methodologist and statistician in clinical and translational research.
Special thoughts to the great working group composed of Telma ROQUE and Jerome Lemonnier from Unicancer and my colleague Julie Henriques from UMQVC.”
Title: Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial
Authors: Etienne Brain, Olivier Mir, Emmanuelle Bourbouloux, Olivier Rigal, Jean-Marc Ferrero, Sylvie Kirscher, Djelila Allouache, Véronique D’Hondt, Aude-Marie Savoye, Xavier Durando, Francois P Duhoux, Laurence Venat-Bouvet, Emmanuel Blot, Jean-Luc Canon, Florence Rollot-Trad, Hervé Bonnefoi, Telma Roque, Jérôme Lemonnier, Aurélien Latouche, Julie Henriques, Magali Lacroix-Triki, Dewi Vernerey
Etienne Brain, Medical Oncologist at Institut Curie/Saint-Cloud, shared Dewi Vernerey’s post:
“Great team. Great aventure. We remember Franck BONNETAIN, to whom we are also beholden.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023